Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies III: Computed Tomography01:27

Imaging Studies III: Computed Tomography

DefinitionComputed Tomography (CT) of the genitourinary (GU) tract is a non-invasive imaging modality that utilizes X-rays and computer processing to generate detailed cross-sectional images of the urinary system, encompassing the kidneys, ureters, bladder, and adjacent structures such as the adrenal glands.PurposeCT scans of the GU tract serve several diagnostic and therapeutic purposes, including:Diagnosis of Urinary Tract Diseases: Detects kidney stones, tumors, cysts, and congenital...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).

British journal of cancer·2013
Same author

Do all patients with bilateral testis cancer have a hereditary predisposition?

International journal of andrology·2007
Same author

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.

The Journal of urology·2007
Same author

Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).

British journal of cancer·2005
Same author

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.

British journal of cancer·2004
Same author

Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.

British journal of cancer·2004

Related Experiment Video

Updated: Jul 29, 2026

An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

A second look at the pT1 G3 bladder tumour.

S J Harland1

  • 1Department of Oncology, Institute of Urology, University College London, UK. jonathan.harland@uclh.org

Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 22, 2005
PubMed
Summary

Intravesical Bacillus Calmette-Guerin (BCG) treatment may help reduce tumor progression in high-risk bladder cancer patients. However, current evidence is mixed, highlighting the need for better methods to identify patients most likely to progress.

Area of Science:

  • Uro-oncology
  • Cancer research
  • Clinical trials

Background:

  • pT1 G3 bladder cancer presents a high risk of tumor progression and mortality.
  • Intravesical Bacillus Calmette-Guerin (BCG) is used for superficial bladder cancer, with extrapolated use in pT1 G3 cases.
  • Adjuvant intravesical BCG after transurethral resection (TUR) shows mixed results in reducing progression for pT1 G3 bladder cancer.

Purpose of the Study:

  • To evaluate the effectiveness of intravesical Bacillus Calmette-Guerin (BCG) in managing pT1 G3 bladder cancer.
  • To review existing data on adjuvant treatments for high-risk bladder cancer.
  • To identify potential prognostic indicators for tumor progression in pT1 G3 bladder cancer.

Main Methods:

  • Review of Phase II studies on adjuvant intravesical BCG post-TUR for pT1 G3 bladder cancer.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

Related Experiment Videos

Last Updated: Jul 29, 2026

An Orthotopic Model of Murine Bladder Cancer
09:07

An Orthotopic Model of Murine Bladder Cancer

Published on: February 6, 2011

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

  • Analysis of a randomized study on adjuvant radiotherapy for pT1 G3 bladder cancer.
  • Assessment of early cystectomy outcomes for high-risk cases.

    • Main Results:

    • Phase II studies suggest a potential benefit of intravesical BCG, but data are inconsistent.
    • Adjuvant radiotherapy did not demonstrate a significant benefit, with high progression rates persisting.
    • Early cystectomy results are often disappointing, possibly due to patient selection issues.

    Conclusions:

    • The efficacy of intravesical BCG for pT1 G3 bladder cancer requires further investigation due to mixed results.
    • Identifying patients at exceptionally high risk of progression remains a clinical challenge.
    • Tumor size, carcinoma in situ, and early recurrence may be prognostic factors, but require more data.